Nosocomial Transmission of Mycobacterium Bovis Resistant to 11 Drugs in People With Advanced HIV-1 Infection

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Nosocomial Transmission of Mycobacterium Bovis Resistant to 11 Drugs in People With Advanced HIV-1 Infection

Lancet (12/13/97) Vol. 350, No. 9093, P. 1738
Guerrero, Antonio; Cobo, Javier; Fortun, Jesus; et al.

Abstract: Researchers from Hospital Ramon y Cajal in Madrid, Spain, investigated the presence of Mycobacterium bovis in a tuberculosis outbreak at the hospital. In the study, 19 patients diagnosed with multidrug-resistant (MDR) tuberculosis due to M. bovis were compared to a control group of 33 randomly selected patients with HIV-1 and a strain of M. tuberculosis susceptible to either isoniazid, rifampicin, or both. The researchers identified 19 cases in the HIV-1 infected patients of primary MDR TB as a result of M. bovis resistant to 11 anti-TB medications. The index case and two other cases in the case group were found to have had previous contact with another hospital that had had an MDR TB epidemic. The researchers note that despite multidrug therapy with both first-line and second-line anti-TB drugs, all patients died after an average of 44 days. They report that "advanced HIV-1 immunosuppression was associated with the development of MDR tuberculosis," and that the implementation of control measures halted the outbreak.

971216
AD972294

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.